Gilead Sciences stock advances as Q2 2026 HIV growth and guidance boost confidence

Gilead Sciences (US3755581036) stock is trading at $138.92 as of August 18, 2026, leaving the shares 28.08% above their 52-week low and 11.68% below their 52-week high per recent market data. This price level comes after the company reported double-digit base business growth in the second quarter of 2026 and reaffirmed its role as a major cash-flow generator in large-cap healthcare.

In its second quarter of 2026, Gilead reported total revenue of $7.8 billion, representing a 10% year-over-year increase and signaling a clear acceleration versus earlier periods. Within that total, product sales reached $7.6 billion, rising 8% year over year and 10% when excluding the declining contribution from COVID therapy Veklury, underscoring that growth is being driven by the companys core franchises rather than pandemic-era windfalls.

Q2 2026 results highlight core growth

Per a detailed earnings summary covering the quarter ended in 2026, Gileads base business sales reached $7.6 billion, up 10% year over year and marking the strongest second quarter base growth in three years. Including Veklury, total product sales were also reported at $7.6 billion, rising 8% year over year and 10% sequentially, which shows that demand is broad-based across the portfolio rather than concentrated in a single therapy line. The company also indicated that illustrative non-GAAP diluted EPS, adjusted for acquisition charges and nonrecurring items, stood at $2.27 for the quarter with growth of 13% year over year, highlighting underlying earnings strength.

The same earnings overview noted that HIV revenue climbed to $5.7 billion in the second quarter, a 12% year-over-year increase and a 13% sequential gain, powered by key therapies such as Biktarvy, Descovy and the newer drug Yeztugo. In oncology, Trodelvy generated $457 million in sales in the quarter, up 26% year over year and 13% sequentially as new indications broadened its use across tumor types. Liver disease medicines contributed $877 million in revenue, up 10% year over year, with Livdelzi alone generating $167 million and more than doubling versus the prior-year quarter while growing 26% sequentially.

The earnings commentary further highlighted that excluding large acquired in-process research and development charges, Gilead delivered an operating margin of 49% in the quarter, paired with a gross margin of 87%. These metrics indicate that the core business remains highly profitable even as the company increases investment in oncology and cell therapy opportunities. At the same time, Gilead incurred around $11.2 billion of acquired in-process R&D expenses tied to transactions with partners such as Arcellx, Tubulis and Ouro, which pushed reported operating margin to negative 94% and non-GAAP diluted EPS to negative $6.75 for the quarter, masking the strength of the ongoing operations in the headline GAAP results.

Guidance and analyst view support the stock

The same second-quarter documentation included updated 2026 guidance that calls for base business sales of $29.8 billion to $30.1 billion, implying 6% to 7% annual growth for the year and a higher midpoint versus earlier forecasts. Total product sales for 2026 are expected to reach $30.1 billion to $30.4 billion, reflecting confidence that HIV, oncology and liver disease therapies can offset the continued decline in Veklury. Management also highlighted that illustrative non-GAAP EPS, adjusted for acquisition-related R&D and nonrecurring royalty items, grew 13% year over year for both the second quarter and the first half of 2026, reinforcing the message of a robust earnings trajectory beneath the accounting impact of recent deals.

Recent coverage of institutional activity notes that shares of Gilead opened at $138.92 on August 18, 2026, on the Nasdaq, with a 12-month low of $108.46 and a 12-month high of $157.29. At that price, the stock trades within a band that leaves room to revisit past highs if the company continues to deliver on its guidance and investors remain comfortable with the heavy front-loaded investment in pipeline expansion. Multiple analyst summaries compiled in the same coverage describe a consensus rating described as Moderate Buy with an average price target of $158.04, indicating that the sell-side community on balance expects further upside relative to the current share price.

In addition to growth and valuation, income-focused investors continue to pay attention to Gileads dividend. According to one recent overview of the companys capital return policy, Gilead has declared a quarterly dividend of $0.82 per share, which translates into an annualized payout of $3.28. At the $138.92 share price level, that equates to a dividend yield close to 2.4%, offering an income stream on top of potential capital appreciation driven by expanding HIV and oncology revenue.

Market performance and valuation context

Market data covering Gilead shares on August 18, 2026, indicate that the stock closed at $138.92 in regular trading. A separate global investing platform that tracks Gilead states that the shares at this level are 28.08% above their 52-week low and 11.68% below their 52-week high, placing the company firmly in recovery territory but not yet at previous peaks. The same snapshot reports that investors see a target price of $157.41 based on consensus projections, which represents an 11.75% potential upside compared with the observed price of $138.92 on that date.

On European trading venues, another quote service that follows Gilead reports a last close of EUR 119.66 on August 17, 2026, for shares traded under the GIS symbol, with an intraday price quote of EUR 118.82 the following session. While currency differences and venue liquidity can influence the exact figures, these Euro-denominated prices align with the U.S. dollar quotes when adjusted for exchange rates, suggesting that Gilead stock is valued consistently across markets. The same valuation page lists a real-time indication of 120.88 EUR in the European session on August 18, 2026, with a 5-day gain of 1.04% and a year-to-date gain of 3.60%, pointing to steady recent momentum.

Investor commentary published on August 18, 2026, portrays Gilead as an underrated turnaround story in healthcare, emphasizing the shift from past periods of stagnant growth driven by declining hepatitis C and COVID revenues to a new phase led by HIV and oncology innovation. This narrative aligns with the reported 10% base business growth in the second quarter and the 26% year-over-year expansion of Trodelvy, as well as the strong double-digit expansion in HIV revenue. For investors, the key takeaway is that the headline GAAP loss in Q2 2026 is primarily the result of strategic acquisitions, while the underlying franchises generate expanding revenue and robust operating margins.

Funds activity further supports the view that the market is warming to Gileads growth and cash-flow profile. A series of filings summarized in recent financial coverage note that multiple institutional investors have increased or initiated positions in the stock in 2026, with the commentary frequently highlighting the combination of a solid dividend, double-digit base business growth and a pipeline strengthened by recent deals. For long-term shareholders, the combination of a 6% to 7% base business growth target for 2026, a dividend payout yielding around 2.4% at current prices and a double-digit consensus price target supports the case for Gilead as a defensive growth name in large-cap biotech.

Key HIV and oncology products

Gileads transformation in recent years is anchored in its HIV portfolio, where flagship regimen Biktarvy has become one of the most widely used single-tablet therapies. The second quarter 2026 revenue figures showing HIV sales of $5.7 billion, up 12% year over year and 13% sequentially, illustrate how these therapies continue to expand even in mature markets. Newer agents such as Yeztugo, mentioned in the same earnings commentary, add to this momentum by addressing evolving treatment needs, including resistance patterns and tolerability considerations in long-term therapy.

Oncology is the second strategic pillar, with Trodelvy standing out as a critical growth driver. The second quarter 2026 sales of $457 million for Trodelvy, accompanied by a 26% year-over-year increase and 13% sequential growth, reflect expanded indications in breast and other cancers and broadened reimbursement access across regions. Management has emphasized that the acquisitions contributing to the $11.2 billion of acquired in-process R&D in Q2 2026 are intended to deepen and diversify this oncology franchise, including next-generation cell therapies and antibody-drug conjugates that could complement Trodelvys current indications.

In liver disease, Gilead remains a significant player with a portfolio that includes the newer agent Livdelzi. The Q2 2026 figures show liver disease revenue of $877 million, up 10% year over year, with Livdelzi accounting for $167 million of that total and more than doubling its revenue compared with the prior-year quarter while rising 26% sequentially. These trends suggest that the companys strategy of leveraging expertise in virology and immunology into adjacent therapeutic areas is gaining traction, offering diversified growth beyond the HIV and oncology franchises.

Stock outlook and investor takeaway

For Gilead stock, the interplay of strong base business growth, significant investment in pipeline assets and a solid dividend shapes the current investment narrative. At a share price of $138.92 as of August 18, 2026, and with a consensus price target of $158.04, investors are weighing the upside implied by analyst models against the accounting complexity introduced by large acquired R&D charges. The second quarter 2026 metrics, including 10% total revenue growth, 10% base business growth and illustrative adjusted EPS of $2.27 with 13% year-over-year growth, provide quantitative support for viewing the company as a maturing growth story rather than a purely defensive income name.

Ultimately, the core question for market participants is whether Gilead can sustain mid-single-digit to high-single-digit base business growth while integrating its recent acquisitions effectively and advancing new oncology and cell therapy candidates through the clinic. If the company meets its 2026 base business sales guidance range of $29.8 billion to $30.1 billion and continues to deliver double-digit growth in key segments such as HIV and oncology, the current discount to the $157.29 52-week high and the consensus target of $158.04 could narrow over time. For now, the combination of robust Q2 2026 results, updated guidance and steady institutional interest keeps Gilead stock positioned as a prominent name in the global biopharmaceutical sector.